Publikationen in Zusammenarbeit mit Forschern von Hospital Clínico San Carlos de Madrid (45)

2015

  1. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

  2. Transarterial chemoembolisation in intermediate-Stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region

    Annals of Hepatology, Vol. 14, Núm. 2, pp. 207-217

2012

  1. Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma

    Oncology, Vol. 82, Núm. 1, pp. 35-40

  2. Relation of IL28b gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease

    PLoS ONE, Vol. 7, Núm. 5

2008

  1. "12 Weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label?

    Scandinavian Journal of Gastroenterology, Vol. 43, Núm. 8, pp. 979-983

  2. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3

    Nature Genetics, Vol. 40, Núm. 5, pp. 623-630

  3. Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients»

    Annals of Hepatology

  4. Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer

    Human Molecular Genetics, Vol. 17, Núm. 23, pp. 3720-3727

2007

  1. GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic

    Journal of Infectious Diseases, Vol. 195, Núm. 9, pp. 1320-1323

2006

  1. Hiperferritinemia hereditaria y sobrecarga férrica: No son sinónimos

    Medicina Clinica

  2. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals

    Molecular Diagnosis and Therapy, Vol. 10, Núm. 1, pp. 29-40

2005

  1. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects

    British Journal of Clinical Pharmacology, Vol. 59, Núm. 1, pp. 62-68

2002

  1. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk

    Cancer Letters, Vol. 180, Núm. 1, pp. 41-46

  2. Severe and disseminated infection by cytomegalovirus in immunocompetent patient

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 19, Núm. 5, pp. 234-236

2001

  1. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk

    Carcinogenesis, Vol. 22, Núm. 8, pp. 1323-1326

  2. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients

    Oncology, Vol. 61, Núm. 1, pp. 59-63

1999

  1. Intermittent obstructive jaundice as a form of presentation of duodenal diverticulum

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 16, Núm. 4, pp. 193-195

1998

  1. Hepatitis G virus infection in Spanish patients with hepatocellular carcinoma

    Liver, Vol. 18, Núm. 4, pp. 255-258

  2. Slow allotypic variants of the NAT2 gene and susceptibility to early- onset Parkinson's disease

    Neurology, Vol. 51, Núm. 6, pp. 1587-1592

1997

  1. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis

    Pharmacogenetics, Vol. 7, Núm. 3, pp. 247-250